- Home
- CERS vs SPXX Comparison
CERS vs SPXX Comparison
Compare CERS & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- SPXX
- Stock Information
- Founded
- CERS 1991
- SPXX 2004
- Country
- CERS United States
- SPXX United States
- Employees
- CERS N/A
- SPXX N/A
- Industry
- CERS EDP Services
- SPXX Trusts Except Educational Religious and Charitable
- Sector
- CERS Technology
- SPXX Finance
- Exchange
- CERS Nasdaq
- SPXX Nasdaq
- Market Cap
- CERS 347.3M
- SPXX 329.9M
- IPO Year
- CERS 1997
- SPXX N/A
- Fundamental
- Price
- CERS $1.40
- SPXX $16.84
- Analyst Decision
- CERS Strong Buy
- SPXX
- Analyst Count
- CERS 2
- SPXX 0
- Target Price
- CERS $3.50
- SPXX N/A
- AVG Volume (30 Days)
- CERS 1.5M
- SPXX 51.3K
- Earning Date
- CERS 05-01-2025
- SPXX 01-01-0001
- Dividend Yield
- CERS N/A
- SPXX 7.55%
- EPS Growth
- CERS N/A
- SPXX N/A
- EPS
- CERS N/A
- SPXX N/A
- Revenue
- CERS $180,270,000.00
- SPXX N/A
- Revenue This Year
- CERS $25.22
- SPXX N/A
- Revenue Next Year
- CERS $10.08
- SPXX N/A
- P/E Ratio
- CERS N/A
- SPXX N/A
- Revenue Growth
- CERS 15.29
- SPXX N/A
- 52 Week Low
- CERS $1.35
- SPXX $13.57
- 52 Week High
- CERS $2.54
- SPXX $16.05
- Technical
- Relative Strength Index (RSI)
- CERS 37.22
- SPXX 34.20
- Support Level
- CERS $1.40
- SPXX $17.00
- Resistance Level
- CERS $1.58
- SPXX $17.47
- Average True Range (ATR)
- CERS 0.08
- SPXX 0.26
- MACD
- CERS 0.00
- SPXX 0.00
- Stochastic Oscillator
- CERS 20.83
- SPXX 28.87
Stock Price Comparison Chart: CERS vs SPXX
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About SPXX Nuveen S&P 500 Dynamic Overwrite Fund
Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.